Dr. Stieglitz will study daraxonrasib in JMML (juvenile myelomonocytic leukemia). JMML is associated with certain PTPN11 variants in Noonan syndrome. #pediatrics #oncosky lnkd.in/p/eDZZ32-x
Daraxonrasib: A Promising Cancer Drug for 2026 | Elliot Stieglitz posted on the topic | LinkedIn
What is the most important cancer drug of 2026? Hands down, that's daraxonrasib. A first-in-class, direct inhibitor of RAS (previously thought to be impossible) that has transformed the field of panc...
lnkd.in